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Abstract
Purpose—Following colonoscopic polypectomy, US Multisociety Task Force (USMSTF) 
guidelines stratify patients based on risk of subsequent advanced neoplasia (AN) using number, 
size, and histology of resected polyps, but have only moderate sensitivity and specificity. We 
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hypothesized that a state-of-the-art statistical prediction model might improve identification of 
patients at high risk of future AN and address these challenges.
Methods—Data were pooled from seven prospective studies which had follow-up ascertainment 
of metachronous AN within 3–5 years of baseline polypectomy (combined n = 8,228). Pooled data 
were randomly split into training (n = 5,483) and validation (n = 2,745) sets. A prognostic model 
was developed using best practices. Two risk cut-points were identified in the training data which 
achieved a 10 percentage point improvement in sensitivity and specificity, respectively, over 
current USMSTF guidelines. Clinical benefit of USMSTF versus model-based risk stratification 
was then estimated using validation data.
Results—The final model included polyp location, prior polyp history, patient age, and number, 
size and histology of resected polyps. The first risk cut-point improved sensitivity but with loss of 
specificity. The second risk cut-point improved specificity without loss of sensitivity (specificity 
46.2 % model vs. 42.1 % guidelines, p < 0.001; sensitivity 75.8 % model vs. 74.0 % guidelines, p 
= 0.64). Estimated AUC was 65 % (95 % CI: 62–69 %).
Conclusion—This model-based approach allows flexibility in trading sensitivity and specificity, 
which can optimize colonoscopy over- versus underuse rates. Only modest improvements in 
prognostic power are possible using currently available clinical data. Research considering 
additional factors such as adenoma detection rate for risk prediction appears warranted.
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Introduction
Colorectal cancer (CRC) is a leading cause of cancer death worldwide. For example, 
annually in the USA, 130,000 individuals develop CRC, and about 50,000 die of the disease 
annually [1]. CRC can be prevented by the identification and removal of colorectal polyps 
[2]. After polypectomy, recommendations are routinely provided for repeat surveillance 
colonoscopy, with the goal of reducing risk of CRC-associated morbidity and mortality 
based on practice guidelines [3]. For example in the USA, current surveillance intervals are 
largely based on US Multisociety Task Force (USMSTF) guidelines, which stratify 
individuals for risk of future advanced neoplasia (AN) based on the number, size, and 
histology of resected polyps.
Although this approach is the standard of care after colonoscopy, evidence suggests that 
current guidelines can be improved [4]. Indeed, the sensitivity and specificity of USMSTF 
guidelines for predicting metachronous AN are estimated to be 59–81 % and 43–58 %, 
respectively [5–9]. Thus, many patients who later develop AN are classified as low risk at 
baseline, and many who remain free of AN on follow-up are classified as high risk at 
baseline. In different patient groups this results in over- or underuse of surveillance 
colonoscopy, exposing many individuals to the risks and costs of unnecessary colonoscopy, 
while others miss an opportunity for early detection and prevention. Improved risk 
stratification strategies are needed.
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Incorporation of additional risk factors beyond the number, size, and histology of resected 
polyps might improve risk stratification. For example, age, sex, body mass index (BMI), and 
polyp location have each been associated with risk of metachronous AN, but have not been 
formally incorporated into risk stratification guidelines [5, 7, 8, 10–12]. Our aim was to 
determine whether a statistical model incorporating additional clinical factors could improve 
post-polypectomy risk stratification compared with USMSTF guidelines, utilizing a large 
pooled dataset of over 8,000 individuals who underwent polypectomy and subsequent 
surveillance colonoscopy.
Materials and methods
Design and participants
Data were pooled from seven prospective studies [13–19] of patients with sporadic 
colorectal adenoma in North America that included 8,228 individuals with polypectomy and 
repeat surveillance colonoscopy within 3–5 years, as previously described [5]. These studies 
ascertained baseline data on patient and adenoma characteristics considered as predictors in 
the analyses and assessed the number, size, histopathology of resected polyps, adenomas, 
and CRCs detected at follow-up.
Primary outcome
The primary outcome was metachronous AN within 3–5 years of polypectomy, defined by 
any of the following: adenoma with size ≥1 cm, high-grade dysplasia, and/or tubulovillous 
or villous histology or adenocarcinoma. AN occurring within 6 months of qualifying 
colonoscopy was counted as part of baseline rather than follow-up findings.
USMSTF guidelines [3]
The USMSTF guideline low-risk group includes patients with 1 or 2 small (<1 cm), tubular 
adenoma(s). The USMSTF guideline high-risk group includes patients with 3–10 adenomas, 
or who have any adenoma with size ≥1 cm, >25 % villous features, or high-grade dysplasia. 
The USMSTF guideline also specifies a very high (highest)-risk group with more than 10 
adenomas. Very few subjects (n = 11) in our data were in highest risk group; therefore, we 
combined high-risk and highest risk subjects into one group.
Baseline risk factors (predictors)
At qualifying colonoscopy, in addition to adenoma size, number, and histology, we 
considered adenoma location (distal colorectum, proximal only, proximal and distal), age, 
sex, race/ethnicity, family history of CRC, cigarette smoking (current, former, never), body 
mass index (BMI), and history of prior polyp. Additionally, unlike current USMSTF 
guidelines, we considered number and size of adenoma(s) as continuous rather than 
categorical variables. To address missing data, we created an unknown category for variables 
for which more than 4 % of patients were missing information including family history of 
CRC, polyp location, and history of previous polyp. Polyps with non-adenomatous histology 
were grouped into one category. Presence of high-grade dysplasia was not characterized by 
two studies; therefore, this variable was characterized as unknown for patients from these 
two studies [14, 16].
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Statistical analysis
All analyses were performed using R [20]. Patients were randomly assigned 2:1 to training 
(n = 5,483) and validation (n = 2,745) datasets. Training data were used to develop our 
prognostic model and identify risk stratification cut-points. Validation data were used to 
compare sensitivity, specificity, and estimated clinical benefit between the model-based risk 
stratification (as developed in the training data) and existing USMSTF guidelines.
Development of the prognostic model—Risk factors that were significantly (p < 0.15) 
associated with the outcome in univariate analysis were considered as potential predictors in 
a multivariable logistic regression model with the outcome AN. We used two 
complementary methods for variable selection that are considered to be superior to 
traditional stepwise model selection approaches [21, 22]. First, an L1-regularized logistic 
regression model (LASSO) [23, 24] was used to assess the order of entry of variables into 
the model, using the glmpath package in R. To assess stability of the entry order, a 
sensitivity analysis using bootstrap LASSO based on 1,000 samples was conducted. Second, 
Bayesian model averaging (BMA) [25] was used for variable selection, implemented in the 
BMA package in R. The performance of the models selected by BMA was compared using 
generalized R2 and Brier’s scores, discrimination was assessed using the area under the 
receiver operating characteristic curve (AUC), and calibration was assessed using the 
Hosmer–Lemeshow goodness-of-fit test [26]. Among the top performing BMA models, we 
prioritized the model which was most consistent with the variables selected by LASSO.
Identification of cut-points for risk stratification—We then used the predicted 
probability of AN from the selected best model to determine a cut-point above which a 
patient would be identified as at high risk of AN. We made an a priori plan to identify two 
risk stratification cut-points. Defining sensitivity as the proportion of individuals with 
metachronous AN at follow-up who were classified as high risk at baseline (Table 1), we 
targeted the first cut-point to achieve a 10 percentage point improvement in sensitivity 
compared with the current USMSTF guidelines. Defining specificity as the proportion of 
individuals without metachronous AN at follow-up who were classified as low risk at 
baseline (Table 1), we targeted the other cut-point to achieve a 10 percentage point 
improvement in specificity [27–29]. The population sensitivity and specificity of USMSTF 
guidelines were estimated on the entire set of pooled data. The cut-point determination 
included all subjects in the training data with defined values for all predictors in the final 
model (including those predictors assigned an unknown category for missing values) and 
used the OptimalCutpoints package in R.
Model validation and comparison of estimated clinical benefit—Model validation 
was performed on all subjects that could be classified by both the model-based method and 
the USMSTF guidelines in the validation dataset. Model discrimination was assessed by the 
AUC. Model calibration was assessed by comparing the predicted risk and observed risk of 
AN for 10 deciles of risk groups. Potential clinical benefit (Table 1) was assessed in the 
validation data using the model coefficients and cut-points identified in the training data, by 
estimated sensitivity and specificity for metachronous AN and estimated rates of over- and 
underuse of colonoscopy. Overuse of surveillance colonoscopy was defined as the 
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proportion of those classified as high risk at baseline who did not develop metachronous AN 
(i.e., 1-positive predictive value). Underuse of surveillance colonoscopy was defined as the 
proportion of those classified as low risk at baseline who developed AN (1-negative 
predictive value). Improvement in specificity and sensitivity using the predictive model on 
the validation data was assessed by McNemar’s test. Differences in overuse and underuse 
between the predictive model and current guidelines were assessed by 95 % confidence 
intervals (CI) based on 1,000 bootstrap samples. Clinical benefit of using the predictive 
model over current guidelines was also assessed using net reclassification improvement 
(NRI) [30].
Results
Analytic cohort selection
The final dataset included 8,228 patients, randomly split into 5,483 training and 2,745 
validation subjects. There were no major differences in baseline patient characteristics 
between the training and validation datasets. Using current USMSTF guidelines, 30.1 % of 
the cohort was classified as low risk, 47.9 % as high risk, and 22 % could not be classified 
due to missing data on adenoma size, adenoma number, histology, or high-grade dysplasia, 
which are required by USMSTF guidelines for risk classification. As described in the 
Methods, the unclassified subjects were included in predictive model development in the 
training data, but were excluded from model assessment and the comparison of the clinical 
benefit between the USMSTF guidelines and the predictive model in the validation data 
(Table 2).
Model development
In univariate analyses of the training dataset, age, sex, history of prior polyps, adenoma 
number, adenoma size, adenoma location, presence of tubulovillous or villous histology, and 
presence of high-grade dysplasia were significantly associated with risk for AN on follow-
up (Table 3). Including these variables in multivariable logistic regression, LASSO variable 
selection and bootstrap samples showed that sex and presence of high-grade dysplasia were 
less important predictors, consistently entering the model last. Considering the top two best 
models selected by BMA, we found that both models did not include sex and high-grade 
dysplasia which was consistent with the LASSO result. We also found that both models 
included age, history of prior polyp, adenoma number, size, and presence of tubulovillous or 
villous histology, while one included adenoma location and the other did not. Since adenoma 
location was identified as an important predictor in LASSO, the model including adenoma 
location was selected as the final model. In the training dataset, the final model had AUC = 
0.68 (95 % CI: 0.66–0.70), with good calibration (goodness-of-fit test p = 0.39).
Identification of cut-points for risk stratification
Based on the entire set of pooled data, the sensitivity and specificity of USMSTF guidelines 
were estimated to be 78 and 41 %, respectively. Using the selected model, two cut-points 
were identified to achieve the targeted sensitivity of 88 % and the targeted specificity of 
51 %, respectively; that is, a 10 percentage point improvement in sensitivity and specificity 
over the guidelines. When targeting improvement in sensitivity, the cut-point of 0.075 for 
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predicted probability of AN was selected, and the actual sensitivity achieved at this cut-point 
was 88.1 % in the training data. When targeting improvement in specificity, the cut-point of 
0.101 was selected, and the actual specificity achieved at this cut-point in the training data 
was 51.2 %. These two cut-points were finalized prior to applying the final predictive model 
to the validation dataset.
Model validation
When applied to the validation data, the AUC of the model was similar to that observed in 
the training data (AUC = 0.65; 95 % CI: 0.62–0.69, Fig. 1). Model calibration was also 
similar, as assessed by goodness-of-fit test (p = 0.21), and ratios of predicted to observed 
risk of AN, which were generally close to 1.00 (range 0.68–1.17, see Table S1, published 
online). The sensitivity and specificity of USMSTF guidelines in the validation data were 
plotted on the same figure (Fig. 1, red dot) and were observed to lie below the model-based 
ROC curve, indicating that the novel model has potential to improve upon risk stratification 
compared to current guidelines across a range of cut-points. For comparison, the sensitivity 
and specificity corresponding to the two a priori identified cut-points are also plotted in Fig. 
1, demonstrating that the first model cut-point (Fig. 1, blue square) had superior sensitivity 
compared to USMSTF guidelines and also demonstrating that the second cut-point (Fig. 1, 
green triangle) had superior specificity compared to USMSTF guidelines.
Comparison of model-based and USMSTF guidelines for risk stratification
We found that USMSTF guideline sensitivity and specificity in the validation data for 
prediction of AN were estimated to be 74 and 42.1 %, respectively, consistent with prior 
reports [5–8]. Further, we found that 83.2 % of individuals classified as high risk at baseline 
by USMSTF guidelines in the validation dataset had no AN on follow-up (consistent with 
surveillance colonoscopy overuse), and 8.9 % classified as low risk developed AN 
(consistent with surveillance colonoscopy underuse). Using the two cut-points identified in 
the training data, we next compared the sensitivity and specificity, underuse and overuse rate 
between the model and the USMSTF guidelines in the validation data (Table 4).
When using the cut-point targeted to improve sensitivity (Fig. 1, blue square), we found 
estimated sensitivity for the model-based rule to be significantly higher than for the 
USMSTF guidelines (88.9 % model vs. 74.0 % guidelines, p < 0.001), correctly identifying 
an additional net 43 subjects as high risk (14.9 % of all patients with AN on follow-up). 
However, there was a significant reduction in specificity when comparing the model-based 
and the USMSTF guidelines (27.7 % model vs. 42.1 % guidelines, p < 0.001), incorrectly 
classifying an additional net 262 subjects as high risk (14.4 % of all patients without AN on 
follow-up). The model-based risk stratification was associated with a 2.9 percentage point 
reduction in estimated surveillance colonoscopy underuse, when compared to the USMSTF 
guidelines (6.0 % model vs. 8.9 % guidelines, p < 0.05), without substantially changing 
estimated surveillance colonoscopy overuse among those classified as high risk (83.7 % 
model vs. 83.2 % guidelines, p > 0.05).
We then investigated the model cut-point targeted to improve specificity (Fig. 1, green 
triangle). Estimated specificity for the model was significantly superior to USMSTF 
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guidelines in the validation data; however, it did not reach the 10 percentage point 
improvement that we targeted in the training data (46.2 % model vs. 42.1 % guidelines, p < 
0.001). At this cut-point, the model correctly identified an additional net 76 subjects as low 
risk (4.2 % of all patients without AN on follow-up). There was no reduction in sensitivity 
(75.8 % model vs. 74.0 % guidelines, p = 0.64), and the model correctly identified an 
additional net 5 patients as at high risk (1.7 % of all patients with AN on follow-up). Model 
performance at this cut-point was associated with a modest absolute reduction in estimated 
surveillance colonoscopy overuse (81.8 % model vs. 83.2 % guidelines, p < 0.05), along 
with a nonsignificant reduction in colonoscopy underuse (7.7 % model vs. 8.9 % guidelines, 
p > 0.05).
Discussion
We have demonstrated that a novel predictive model for metachronous AN, together with an 
a priori established risk cut-point, can modestly improve specificity (46.2 % model vs. 
42.1 % guidelines, p < 0.001) with no deterioration in sensitivity (75.8 % model vs. 74.0 % 
guidelines, p = 0.64), when compared to current USMSTF guidelines for post-polypectomy 
risk stratification. Our predictive model was developed using best statistical practices for 
predictive modeling on one of the most comprehensive datasets available. These practices 
include a priori specification of the model and cut-point development in the training data 
using optimal prediction strategies, and prespecifying the testing plan in the validation data. 
Statistical theory thus supports that the model likely represents a near optimal prediction rule 
based on available data, which is an advantage of a model-based approach over more ad hoc 
approaches. The improved test characteristics we observed were likely due to selection of 
additional variables into the final model which are not used by USMSTF guidelines, and 
also by employing some variables as continuous rather than categorical predictors (e.g., 
considering the absolute number of adenomas in the predictive model rather than 
categorizing the number of adenomas as 3 or more, or less than 3, as in the USMSTF 
guidelines). Although the magnitude of the estimated benefit was rather modest, our work 
provides proof of concept that improved modeling techniques and additional variables, 
beyond adenoma number, size, and histology as used for USMSTF guideline-based 
management, have potential to improve risk stratification of individuals with colorectal 
polyps, and merit further investigation.
An additional advantage of model-based risk stratification is the ability to tune sensitivity 
and specificity to clinical needs more finely by choosing a clinically appropriate cut-point. 
Indeed, as seen from Fig. 1, a risk cut-point to maximize sensitivity or specificity could be 
identified. Thus, the model could be used to select strategies for surveillance that maximizes 
either sensitivity or specificity depending on the priorities of patients, physicians, or policy 
makers. For example, use of the cut-point targeted to improve sensitivity in practice would 
have resulted in detection of an additional 14.9 % of all individuals with metachronous AN 
on follow-up. In situations with strained colonoscopy resources, or for patients at increased 
risk for colonoscopy associated complications due to factors such as age, use of the cut-point 
targeted to improve specificity could have resulted in reduced colonoscopy use, without an 
increase in underuse for individuals who developed metachronous AN. These examples also 
illustrate how a model-based approach can be used to investigate the balance between 
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estimated population level costs of surveillance colonoscopy overuse and underuse across a 
range of risk stratification cut-points.
A number of cohort and case–control studies have identified risk factors for metachronous 
AN after initial polypectomy [6, 8, 10, 11, 31–45]. These include patient characteristics 
(age, sex, BMI, diabetes, and family history of CRC), polyp characteristics (adenoma size, 
number, location), and histology (villous and/or high-grade dysplasia). We also found many 
of these characteristics to be associated with risk of metachronous AN in our analysis. 
However, unlike prior reports, we extended our identification of risk factors for 
metachronous AN to develop and validate a statistical model for predicting this outcome. To 
our knowledge, there have not been previous reports of comprehensive statistical models that 
take into account multiple characteristics, and compare performance to established practice 
guidelines. As such, our findings confirm and extend prior work seeking to improve risk 
stratification of individuals after baseline polypectomy. In addition, our model-based 
stratification rule was based on choosing appropriate cut-points for predicted probability of 
risk and the performance of the risk stratification was evaluated through sensitivity and 
specificity, a strategy not commonly reported though it has the advantage of statistical rigor 
and direct clinical relevance.
Notably, our targeted cut-points, which aimed to achieve substantial improvements in either 
sensitivity or specificity, could not simultaneously improve sensitivity and specificity. This 
illustrates the limits of the potential improvements supported by the current data and 
highlights the need for incorporation of data from additional risk factors, which might 
support further improvements in overall prognostic power. It is likely that additional 
variables will need to be identified in order to achieve the goal of substantially improving 
both specificity and sensitivity at the same time. Although we included key patient and 
polyp characteristics that were not taken into account by USMSTF guidelines in our 
predictive model, there are other variables that might be influential but were not considered. 
For example, the adenoma detection rate has been found to be significantly associated with 
interval CRC after colonoscopy [46, 47], but was not available for our study. Colonoscopy is 
an operator-dependent test with performance characteristics (such as adenoma detection 
rate) varying within endoscopist and other factors [48]. Thus, indicators of the quality of 
colonoscopy are natural further candidates that could be considered in risk classification 
[35]. Indeed, because of the observed close relationship between colonoscopist adenoma 
detection rate and risk for interval cancer after colonoscopy [46, 47], it is possible that this 
parameter might be a very powerful prognostic variable for metachronous neoplasia. Aspirin 
and dietary variables, such as red meat, processed meat, and fiber, have also been linked 
with risk for CRC and may also be considered as candidate variables for risk stratification 
for metachronous advanced neoplasia [5]. It is likely that additional variables (such as 
adenoma detection rate and aspirin exposure) would have a substantial impact on the ability 
of the model to correctly identify both high-risk and low-risk patients. For variables already 
considered in the predictive model, additional information (such as types of previous polyp, 
serrated or not) might also improve model performance.
Several limitations may be considered in interpreting this work. First, colonoscopies 
contributing data to this study were performed between 1984 and 1998. Changes in 
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colonoscopy quality may have occurred over time, such that individuals encountered in 
clinical practice now might be at different risk of metachronous AN than the individuals 
included in this study. Second, six of the seven studies contributing to this analysis were 
from prevention trials, and in two of the trials (one of aspirin, the other of calcium 
supplementation) a modest degree of intervention efficacy was shown. Further, studies 
contributing data were not limited to individuals undergoing first time colonoscopy. We are 
unable to ascertain whether these issues might have resulted in inclusion of a study 
population that was at higher or lower risk of advanced metachronous neoplasia compared 
with the general population. Thus, patients from included trials may not be representative of 
the general population of individuals with adenomas. Third, our training and validation sets 
were a random split of a larger dataset, and we did not have additional independent 
validation datasets available. Fourth, analyses may have been affected by the detail of 
variable ascertainment. For example, we used history of prior polyp as a predictor variable, 
but do not have detail on type of prior polyp. It is possible that within the prior polyp 
category, it is only those with prior history of AN who have increased risk. Fifth, some 
predictors had a high percentage of missing data (24 % for high-grade dysplasia and 21 % 
for history of previous polyps). We included an ‘unknown’ category for these variables in 
order to retain more subjects in the analysis and improve the study power. Note that our 
focus in this study is risk prediction, and optimal methods to address missing data in this 
context are an area of active statistical research. Further, family history data were collected 
differently across studies, and were aggregated in this analysis as history of CRC in one or 
more parents, siblings, or children. Details such as prior polyp type and relationship and age 
of family members with CRC were not available for analysis, and may have affected the 
performance of these variables in our models. All of these limitations might be addressed in 
the future by conducting analyses using large clinical datasets collected as part of usual care, 
or by developing prospective registries of patients undergoing polypectomy, with careful 
data collection.
In conclusion, our results suggest that a predictive model including polyp and patient 
characteristics can be used to improve post-polypectomy risk stratification. Such a model 
has potential to reduce the unnecessary colonoscopy risks and costs for low-risk patients and 
identify high-risk individuals who might benefit from early surveillance colonoscopy. 
However, in order to substantially improve prognostic models for planning colonoscopy 
surveillance, additional clinical variables associated with colonoscopy outcomes appear to 
be needed. In ongoing work, we will incorporate quality factors and other additional patient 
and polyp factors to build on our current methodology for predicting metachronous AN after 
initial polypectomy. More research is needed to develop and validate prognostic models for 
planning colonoscopy surveillance, and this should eventually lead to prospective trials that 
test model-based strategies for surveillance.
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Fig. 1. 
ROC curve for the predictive model using validation data. This graph demonstrates the 
potential advantage of using a continuous predictive model for risk stratification. Cut-points 
for probability of metachronous advanced neoplasia, which were estimated by the predictive 
model, can be identified to improve either sensitivity or specificity over the USMSTF 
guidelines. The red dot represents the sensitivity and specificity estimated by the USMSTF 
guidelines in the validation data. The blue square represents the estimated sensitivity and 
specificity in the validation data corresponding to the cut-point targeted for improved 
sensitivity over USMSTF guidelines. The green triangle represents the estimated sensitivity 
and specificity in the validation data corresponding to the cut-point identified in the test data 
targeted to improve specificity over the USMSTF guidelines. (Color figure online)
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Table 1
Glossary of risk stratification terms [49]
Sensitivity (true positive rate) proportion of individuals with metachronous advanced neoplasia at follow-up who was classified as ‘high risk’ at 
baseline by classification strategy (i.e., predictive model or guidelines)
Specificity (true negative rate) proportion of individuals without metachronous advanced neoplasia at follow-up who was classified as ‘low risk’ 
at baseline by classification strategy
Positive predictive value (PPV) proportion of individuals with metachronous advanced neoplasia at follow-up among those who were classified 
by a strategy as ‘high risk’ at baseline
Negative predictive value (NPV) proportion of individuals without metachronous advanced neoplasia at follow-up among those who were 
classified by a strategy as ‘low risk’ at baseline
Surveillance colonoscopy overuse rate (1-PPV) proportion of individuals without metachronous advanced neoplasia at follow-up among those 
who were classified by a strategy as ‘high risk’ at baseline
Surveillance colonoscopy underuse rate (1-NPV) proportion of individuals with metachronous advanced neoplasia at follow-up among those 
who were classified by a strategy as ‘low risk’ at baseline
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Table 2
Patient characteristics for the study cohort, stratified by training versus validation dataset assignment
Total (n = 8,228)
n (%)
Training (n = 5,483)
n (%)
Validation (n = 2,745)
n (%) p value
a
Demographics
Age (year)
 Mean (SD) 62.1 (9.42) 62.1 (9.43) 62.0 (9.41) 0.42
BMI
 Mean (SD) 27.5 (4.43) 27.5 (4.42) 27.6 (4.47) 0.60
Sex
 Female 2,374 (28.9) 1,566 (28.6) 808 (29.4) 0.42
 Male 5,845 (71.1) 3,917 (71.4) 1,937 (70.6) 0.42
Race/ethnicity
 White 7,316 (88.9) 4,870 (88.8) 2,466 (89.1) 0.91
 African-American 461 (5.6)  311 (5.7)  150 (5.5)  
 Others 451 (5.5)  302 (5.5)  149 (5.4)  
Family history of colorectal cancer
 No 5,818 (70.7) 3,840 (70.0) 1,978 (72.1) 0.04
 Yes 1,879 (22.8) 1,265 (23.1) 614 (22.4)
 Unknown 531 (6.5)  378 (6.9)  153 (5.6)  
Cigarette smoker
 Never 2,805 (34.3) 1,906 (34.9) 899 (32.9) 0.18
 Former 4,081 (49.9) 2,695 (49.4) 1,386 (50.8)
 Current 1,299 (15.9) 853 (15.6) 446 (16.3)
Personal history of previous polyp
 No 4,447 (54)   2,967 (54.1) 1,480 (53.9) 0.18
 Yes 2,057 (25)   1,342 (24.5) 715 (26)   
 Unknown 1,724 (21)   1,174 (21.4) 550 (20)   
Adenoma characteristics
Number (count)
 Mean (SD) 1.73 (1.28) 1.73 (1.26) 1.74 (1.33) 0.85
Size of largest (mm)
 Mean (SD) 8.14 (6.20) 8.23 (6.30) 7.95 (6.00) 0.02
Locationb
 Distal colorectum 3,867 (47)   2,578 (47)   1,289 (47)   0.31
 Proximal only 2,482 (30.2) 1,657 (30.2) 825 (30.1)
 Proximal and distal 1,553 (18.9) 1,017 (18.5) 536 (19.5)
 Unknown 326 (4.0)  231 (4.2)  95 (3.5)  
Histology
 Tubular 5,576 (67.8) 3,729 (68)   1,847 (67.3) 0.75
 Tubullovillous or villous 1,728 (21)   1,147 (20.9) 581 (21.2)
 Unknown and others 924 (11.2) 607 (11.1) 317 (11.5)
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Total (n = 8,228)
n (%)
Training (n = 5,483)
n (%)
Validation (n = 2,745)
n (%) p value
a
High-grade dysplasia
 No 5,630 (68.4) 3,747 (68.3) 1,883 (68.6) 0.91
 Yes 599 (7.3)  404 (7.4)  195 (7.1)  
 Unknownc 1,999 (24.3) 1,332 (24.3) 667 (24.3)
Predicted risk of advanced adenoma on follow-upd 0.53
 High risk 2,477 (30.1) 1,635 (29.8) 842 (30.7)
 Low risk 3,939 (47.9) 2,649 (48.3) 1,290 (47.0)
 Unknownc 1,812 (22.0) 1,199 (21.9) 613 (22.3)
ap value is for comparing the distribution of variables between training and validation datasets
bAdenoma location is defined as proximal (cecum, ascending colon, hepatic flexure, transverse colon, and splenic flexure) or distal (descending 
colon, sigmoid colon, and rectum)
c
Presence of high-grade dysplasia was not characterized by AFT and CPPS studies, this variable was characterized as unknown for patients from 
these two studies
d
Risk of advanced adenoma was classified using USMSTF guidelines, subjects were classified as unknown if missing adenoma size, adenoma 
number, histology, or high-grade dysplasia
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Table 3
Factors associated with metachronous advanced neoplasia, training data
Unadjusteda Adjustedb
OR (95 % CI) p value OR (95 % CI) p value
Demographics
Age (per year) 1.04 (1.03–1.05) <0.001 1.03 (1.02–1.04) <0.001
BMI 1.01 (0.99–1.03)   0.17
Sex
 Female Ref
 Male 1.24 (1.03–1.50)   0.02
Race/ethnicity
 White Ref
 African-American 1.00 (0.71–1.42)   0.99
 Other 0.88 (0.61–1.28)   0.51
Family history of colorectal cancer
 No Ref
 Yes 1.04 (0.86–1.26)   0.68
 Unknown 1.07 (0.78–1.47)   0.68
Cigarette smoker
 Never Ref
 Former 1.10 (0.92–1.31)   0.31
 Current 0.97 (0.75–1.25)   0.80
Personal history of previous polyp
 No Ref Ref
 Yes 1.45 (1.21–1.75) <0.001 1.50 (1.23–1.84)   0.001
 Unknown 0.85 (0.68–1.07)   0.16 0.90 (0.71–1.14)   0.38
Adenoma characteristics
Number (per adenoma) 1.25 (1.19–1.32) <0.001 1.13 (1.06–1.21) <0.001
Size (per mm) 1.05 (1.04–1.06) <0.001 1.03 (1.02–1.04) <0.001
Location
 Distal colorectum Ref Ref
 Proximal only 1.44 (1.19–1.76) <0.001 1.41 (1.14–1.74)   0.002
 Proximal and distal 2.25 (1.83–2.76) <0.001 1.51 (1.17–1.95)   0.002
 Unknown 1.08 (0.69–1.70)   0.73 0.96 (0.58–1.61)   0.88
Histology
 Tubular Ref Ref
 Tubullovillous or villous 2.11 (1.76–2.54) <0.001 1.63 (1.32–2.00) <0.001
 Unknown/other 1.31 (1.01–1.71)   0.04 1.09 (0.83–1.45)   0.53
High-grade dysplasia
 No Ref
 Yes 1.81 (1.38–2.36) <0.001
 Unknown CPPS 1.23 (0.96–1.58)   0.11
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Unadjusteda Adjustedb
OR (95 % CI) p value OR (95 % CI) p value
 Unknown AFT 0.85 (0.65–1.10)   0.22
aUnadjusted OR from simple logistic regression model
bAdjusted OR from the best selected multivariable logistic regression model. Note that the ORs are not available for risk factors that were not 
selected in the best model. Ref, reference group
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Table 4
Net clinical benefit of the novel model versus USMSTF guidelines using model cut-points targeted to improve 
(a) sensitivity, and (b) specificity, applied to the validation dataset
Model cut-point strategy Measure of 
clinical benefit
Validation dataset results
USMSTF guidelines (%) Predictive model (%) Difference (95 % CI)a
Improve sensitivity compared to USMSTF guidelines
Specified sensitivity within training 
data: 88 %
Sensitivity 74.0 88.9
  14.9 (9.5, 20.2)***
 Resulting cut-point = 0.075 Specificity 42.1 27.7
−14.4 (−16.7, −11.9)***
Overuse 83.2 83.7     0.5 (−0.6,1.6)
Underuse   8.9   6.0
  −2.9 (−5.0, −0.9)†
Improve specificity compared to USMSTF guidelines
 Specified specificity within training 
data = 51 %
Sensitivity 74.0 75.8     1.8 (−4.2, 7.4)
 Resulting cut-point = 0.101 Specificity 42.1 46.2
    4.1 (2.0, 6.7)***
Overuse 83.2 81.8
  −1.4 (−2.7, −0.1)†
Underuse   8.9   7.7   −1.2 (−3.0, 0.6)
a
Difference is the estimate using predictive model minus the estimate using US guidelines and 95 % CI is based on 1,000 bootstrapped samples
*p value < 0.05;
**p value < 0.01;
***p value < 0.001;
†Statistically significant at alpha = 0.05 based on 95 % bootstrap CI
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